Modulation of intracellular Ca2+ via L-type calcium channels in heart cells by the autoantibody directed against the second extracellular loop of the alpha1-adrenoceptors

Can J Physiol Pharmacol. 2003 Mar;81(3):234-46. doi: 10.1139/y03-044.

Abstract

The effects of methoxamine, a selective alpha1-adrenergic receptor agonist, and the autoantibody directed against the second extracellular loop of alpha1-adrenoceptors were studied on intracellular free Ca2+ levels using confocal microscopy and ionic currents using the whole-cell patch clamp technique in single cells of 10-day-old embryonic chick and 20-week-old fetal human hearts. We observed that like methoxamine, the autoantibody directed against the second extracellular loop of alpha1-adrenoreceptors significantly increased the L-type calcium current (I(Ca(L))) but had no effect on the T-type calcium current (I(Ca(T))), the delayed outward potassium current, or the fast sodium current. This effect of the autoantibody was prevented by a prestimulation of the receptors with methoxamine and vice versa. Moreover, treating the cells with prazosin, a selective alpha1-adrenergic receptor antagonist blocked the methoxamine and the autoantibody-induced increase in I(Ca(L)), respectively. In absence of prazosin, both methoxamine and the autoantibody showed a substantial enhancement in the frequency of cell contraction and that of the concomitant cytosolic and nuclear free Ca2+ variations. The subsequent addition of nifedipine, a specific L-type Ca2+ channel blocker, reversed not only the methoxamine or the autoantibody-induced effect but also completely abolished cell contraction. These results demonstrated that functional alpha1-adrenoceptors exist in both 10-day-old embryonic chick and 20-week-old human fetal hearts and that the autoantibody directed against the second extracellular loop of this type of receptors plays an important role in stimulating their activity via activation of L-type calcium channels. This loop seems to have a functional significance by being the target of alpha1-receptor agonists like methoxamine.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-1 Receptor Agonists
  • Aniline Compounds
  • Animals
  • Autoantibodies / pharmacology*
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / physiology*
  • Calcium Channels, T-Type / physiology
  • Cells, Cultured
  • Chick Embryo
  • Fetus
  • Fluorescent Dyes
  • Humans
  • Methoxamine / pharmacology
  • Myocardial Contraction
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / physiology*
  • Nifedipine / pharmacology
  • Patch-Clamp Techniques
  • Potassium Channels / drug effects
  • Potassium Channels / physiology
  • Receptors, Adrenergic, alpha-1 / immunology
  • Receptors, Adrenergic, alpha-1 / physiology*
  • Sodium Channels / drug effects
  • Sodium Channels / physiology
  • Xanthenes

Substances

  • Adrenergic alpha-1 Receptor Agonists
  • Aniline Compounds
  • Autoantibodies
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Calcium Channels, T-Type
  • Fluorescent Dyes
  • Potassium Channels
  • Receptors, Adrenergic, alpha-1
  • Sodium Channels
  • Xanthenes
  • Fluo-3
  • Methoxamine
  • Nifedipine
  • Calcium